The Unflattering Mirror of Valuation
Let’s not beat around the bush. The core of this issue is money. European pharmaceutical giants are looking across the Atlantic and seeing their American cousins valued at far more generous multiples. It’s like two identical houses on the same street, but one is inexplicably priced 30 percent higher because it’s in a slightly trendier postcode. For a CEO and a board, whose job is to maximise shareholder value, that kind of discount becomes impossible to ignore.
AstraZeneca, for instance, earns a huge chunk of its revenue in the United States. Yet, its shares are priced according to the more, shall we say, reserved tastes of the London market. European investors have traditionally been a cautious bunch, valuing steady dividends over the speculative, high-growth narrative that American markets seem to adore. The question for these companies is simple: why stay where you’re merely appreciated, when you could go where you might be celebrated?